Signify Premium Insight: The Tightrope Upon Which Lunit Must Walk

That Lunit has decided to place its fortunes in the hands of public investors should come as no surprise. As detailed in a recent Premium Insight discussing medical imaging AI vendors with more than $100m of venture funding, Lunit, like many of its successful peers shares some common traits. The vendor has, for instance, taken a very robust approach to product development. Instead of relying solely on one of the available training datasets, which can introduce some ambiguity and aren’t always perfectly labeled, Lunit has chosen to use training data validated against biopsy results. This helps ground the AI tool’s algorithm and minimise the likelihood of errors. A tool is only as good as the data it is fed so supplementing images with other clinical data is a prudent approach.